CharlesJoelRosserMDMBA
Urology • Los Angeles, CASurgical Oncology
Professor and Medical Director Cedars-Sinai CANCER Clinical Trials Office
Dr. Rosser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
Los Angeles, CA 90048
Summary
- Dr. Charles Rosser is an urologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. He received his medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 23 years. He specializes in surgical oncology and is experienced in bladder tumors, clinical research, and turbt.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2000 - 2003
Wake Forest University Baptist Medical CenterResidency, Urology, 1994 - 2000
Rutgers Robert Wood Johnson Medical SchoolClass of 1994
Certifications & Licensure
CA State Medical License 2018 - 2026
HI State Medical License 2013 - 2024
FL State Medical License 2003 - 2023
NC State Medical License 2005 - 2017
TX State Medical License 2000 - 2017- American Board of Urology Urology
Clinical Trials
- Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer Start of enrollment: 2003 Nov 01
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 58 citationsSyn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancerMotoyuki Yamashita, Charles J. Rosser, Jain Hua Zhou, Xin Qiao Zhang, Robert J. Connor
Cancer Gene Therapy. 2002-08-01 - 9 citationsClinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.Michael Nazmifar, Cheyenne Williams, Aurash Naser-Tavakolian, John Heard, Charles Rosser
The Journal of Urology. 2023-01-01 - 86 citationsPheochromocytoma of the urinary bladder: a systematic review of the contemporary literature.Jonathan Beilan, Adrienne Lawton, Julio Hajdenberg, Charles J. Rosser
BMC Urology. 2013-04-29
Press Mentions
New Bladder Cancer Diagnostic Receives Approval for Sale in EuropeJune 22nd, 2022- Nonagen Bioscience Announces CE Mark for Oncuria® Bladder Cancer DiagnosticJune 16th, 2022
- Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer TestMay 12th, 2022
- Join now to see all
Grant Support
- Multiplexed protein biomarker for the non-invasive detection of bladder cancerNCI2016–2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
